HealthCor Management

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethal contexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials.

Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.

Ikena Oncology discovers and develops biomarker-driven therapies for cancer patients. The company focuses on developing novel cancer therapies that drive the formation and spread of cancer. Ikena Oncology provides medical needs by discovering chemistry, translational science, and patient-centric drug development.

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, and minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, and minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.

PreemaTEX is the developer of an innovative, high value diagnostic tests focused on assessing a woman’s risk for preterm delivery early in pregnancy.

ReShape Medical Inc. is a medical device company specializing in non-surgical weight loss solutions for individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30-40. The company offers the ReShape procedure, which utilizes a dual intragastric balloon system combined with a personalized one-year weight loss program, aimed at facilitating weight loss through lifestyle changes. This procedure is designed for adult patients who have not achieved success with diet and exercise alone. ReShape Medical operates through medical weight loss centers and is based in San Clemente, California. Originally founded as Abdominis, Inc. in 2005, the company was rebranded and operates as a subsidiary of ReShape Lifesciences Inc. The broader product portfolio of its parent company includes other minimally invasive devices for treating obesity and metabolic diseases.

HLS Therapeutics Inc is a specialty pharmaceutical company focused on the acquisition and commercialization of branded pharmaceutical products in North America. The company is dedicated to managing the life cycles of these products after exclusivity, ensuring the availability of essential treatments for patients and caregivers. HLS's portfolio includes notable products such as Clozaril, Vascepa, and CSAN Pronto. The majority of the company's revenue is generated through product sales, supplemented by royalties. HLS operates primarily in Canada and the United States, as well as in other international markets.

Natera, Inc. is a diagnostic company that specializes in preconception and prenatal genetic testing services. Its primary offerings include the Panorama test, which is a non-invasive prenatal test that screens for chromosomal abnormalities in a fetus through a blood sample from the mother, and the Vistara test, designed to identify single-gene disorders. Additionally, Natera provides Horizon carrier screening to determine genetic disease carrier status and Spectrum, which analyzes chromosomal anomalies during in vitro fertilization. The company also offers Anora, a test for analyzing fetal chromosomes to investigate miscarriage causes, and non-invasive paternity testing. Its Signatera product utilizes circulating tumor DNA technology to monitor cancer recurrence. Natera markets its tests through a direct sales force and a network of approximately 100 laboratory and distribution partners both domestically and internationally. The company, founded in 2003 and headquartered in San Carlos, California, maintains partnerships with BGI Genomics and Foundation Medicine for the development of genetic testing assays.

CareView Communications develops a proprietary network system that can be deployed throughout a healthcare facility using the existing coaxial cable infrastructure and provides a suite of software applications designed to reduce patient falls, streamline workflow and improve HCAHPS scores. Real-time patient monitoring enhances safety and security while Virtual Bed Rails (R) and Virtual Chair Rails (R) prevent falls BEFORE they happen. The bed management program provides a real-time dashboard of bed status of all hospital beds, for patient placement and the prevention of overcrowding. CareView Mobile is a point-of-care application that allows nursing to see, communicate with and manage patients from the palm of their hand. Voice (VoIP), text and email capability allow staff members to communicate with ease and efficiency. A guest services package provides a suite of entertainment features to increase patient satisfaction and the overall hospital experience and a patient education portal provides convenient, click-of-a-button access to a collection of education, to inform and educate the patient and their family.

Sadra Medical is exploring new minimally invasive alternatives to traditional surgical valve replacement. The company hopes that devices allowing such procedural advances will facilitate and enhance treatment of aortic valve disease. Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today. Sadra Medical, a subsidiary of Boston Scientific.

Access Closure, Inc., a medical device company, provides access site management products to address the complex challenge of vascular closure during interventional and diagnostic procedures. The company's products include Mynx delivery system, a vascular closure device that seals the arteriotomy using a water-soluble and extravascular sealant, which expands in the tissue tract by absorbing blood and subcutaneous fluids. Access Closure, Inc. was founded in 2002 and is based in Mountain View, California.

ApaTech Ltd., an ortho-biologics company, produces synthetic bone repair materials. It offers Actifuse, a synthetic bone graft, which creates a material that promotes the formation of bone and increases the volume of bone formed in the graft/host bone composite structures for small void filling and spinal fusion applications. The company also provides ApaPore, a synthetic and porous hydro-xyapatite grafting for the cemented revision of failed total joint arthroplasties for spinal fusions and fracture fixations, as well as for treating bone defects; and Actifuse MIS Bone Graft Delivery System that offers controlled delivery and precise placement for surgeons performing open and minimally invasive procedures, as well as for use in various spinal and orthopedic procedures, including posterolateral fusion, bone void filling, and acetabular cysts. It offers its products through distributors in the United Kingdom, Ireland, Norway, Sweden, Germany, Austria, Spain, Portugal, Italy, Greece, Turkey, Kuwait, Syria, Australia, and New Zealand. ApaTech Ltd. was founded in 2001 and is based in Elstree, the United Kingdom. It has operations in London, the United Kingdom; Foxborough, Massachusetts; and Berlin, Germany.

Paradigm Spine, LLC (Paradigm Spine) is a privately-held medical device company, engaged in the development of spinal implants for the spine and orthopedic markets. It develops non fusion spinal implants, motion preserving products and tissue sparing products. Paradigm Spine's product Coflex, an interspinous implant used in the treatment of facet arthosis and decompressive procedures. Its products are used for spinal stabilization, rebalances spinal segment and restores natural anatomical function. The company is headquartered in New York, the US. The company also focused on the development of DSS system, a minimally-invasive pedicle-screw based system, which received a European CE Mark in April 2007 and FDA market clearance in January 2008.

Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.

HeartFlow focuses on precision heart care, combining human ingenuity with technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe, and Japan.

Paradigm Spine, LLC (Paradigm Spine) is a privately-held medical device company, engaged in the development of spinal implants for the spine and orthopedic markets. It develops non fusion spinal implants, motion preserving products and tissue sparing products. Paradigm Spine's product Coflex, an interspinous implant used in the treatment of facet arthosis and decompressive procedures. Its products are used for spinal stabilization, rebalances spinal segment and restores natural anatomical function. The company is headquartered in New York, the US. The company also focused on the development of DSS system, a minimally-invasive pedicle-screw based system, which received a European CE Mark in April 2007 and FDA market clearance in January 2008.